Fellow shareholders, the merger is reducing our KERX holdings by 62.5% — what are we getting in return.
AKBA shareholders are getting diluted by some 55 million shares which the company will be issuing — they get to keep all their shares. And, in return for the company issuing some 55 million shares, they get Keryx Pharmaceuticals with blockbuster potential Auryxia which has a multi-billion addressable market as we speak, 2 FDA approvals, EU approval, years of groundwork development, years payor coverage development, years of sales and marketing development, expanded 27,300 sq. ft. offices with multi-million renovations, years of sales in the books, manuf. agreements in place, EU groundwork in place, etc. etc. etc.
What are we getting for 62.5% of out shares? Folks, we are potentialy being robbed.
Class-action lawsuit?
ALL above, in my opinion...
